[4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-carbamic acid 4-nitro-phenyl ester; hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: [4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-carbamic acid 4-nitro-phenyl ester; hydrochloride
• 英文别名: (4-nitrophenyl) N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]carbamate;hydrochloride
• 化学式: C₂₃H₁₈N₆O₄*ClH
• 分子量: 478.895
• InChiKey: YHTRSMQZAFEKSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.53
• 重原子数：
  34.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  132.17
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  三甲基-1,3-丙二胺 、 [4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-carbamic acid 4-nitro-phenyl ester; hydrochloride 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases

  摘要：

  The constitutively active Abl kinase activity of the Bcr-Abl oncoprotein is causative for chronic myelogenous leukemia. Urea derivatives, structurally related to the therapeutic agent ST1571, have been identified, which potently inhibit the tyrosine kinase activity of recombinant Abl. In particular a dimethylamino-aniline derivative (18) inhibited c-Abl transphosphorylation with an IC50 value of 56nM. Although this activity was not translated into cellular activity against the constitutively activated oncogenic Bcr-Abl, a number of compounds from this series potently inhibited cellular PDGFR autophosphorylation. It was also possible to differentiate between c-Abl and PDGFR kinase inhibition, with compound 22 being selective towards AN and 23 selective for PDGFR. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.042
• 作为产物：
  描述：

  2-氨基-4-硝基甲苯 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 二氯甲烷 、 正丁醇 为溶剂， 反应 2.0h， 生成 [4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-carbamic acid 4-nitro-phenyl ester; hydrochloride
  参考文献：
  名称：

  Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases

  摘要：

  The constitutively active Abl kinase activity of the Bcr-Abl oncoprotein is causative for chronic myelogenous leukemia. Urea derivatives, structurally related to the therapeutic agent ST1571, have been identified, which potently inhibit the tyrosine kinase activity of recombinant Abl. In particular a dimethylamino-aniline derivative (18) inhibited c-Abl transphosphorylation with an IC50 value of 56nM. Although this activity was not translated into cellular activity against the constitutively activated oncogenic Bcr-Abl, a number of compounds from this series potently inhibited cellular PDGFR autophosphorylation. It was also possible to differentiate between c-Abl and PDGFR kinase inhibition, with compound 22 being selective towards AN and 23 selective for PDGFR. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.042